Mariachiara Santorsola

Mariachiara Santorsola

Auto-generated profile, based on publicly available information

Mariachiara Santorsola

Istituto Nazionale Tumori di Napoli, IRCCS “G. Pascale”, 80131 Naples, Italy

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2026 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
RSRoberto Sirica
Roberto Sirica
CPCarmine Picone
Carmine Picone
Francesco SabbatinoFrancesco Sabbatino
Francesco Sabbatino
NPNadia Petrillo
Nadia Petrillo
MCMarco Cascella
Marco Cascella
AOAlessandro Ottaiano
Alessandro Ottaiano
Aim: The aim of this study is to investigate the molecular and functional features underlying the clinical heterogeneity between oligometastatic (OM) and polymetastatic (PM) colon cancer. Methods: We performed a genotype-phenotype analysis in a homogeneous cohort of 127 patients with metastatic colon cancer (mCC) profiled using the same next-generation sequencing platform (TruSight Oncology® 500). OM disease was defined as the presence of one to three metastatic lesions per involved organ, involving no more than two organs overall, with all lesions measuring < 70 mm in maximum diameter and no single lesion > 25 mm. Molecular alterations, microsatellite instability (MSI), tumor mutational burden (TMB), and overall survival (OS) were analyzed. Gene Ontology (GO) enrichment and Phenolyzer network analyses were applied to explore functional differences between prognostically distinct molecular subgroups. Results: OM patients showed a striking survival advantage compared with PM patients [median OS not reached versus 29 months; hazard ratio (HR): 0.20, P < 0.0001], validating the clinical distinction between the two phenotypes. PM disease was significantly enriched for RAS mutations, whereas OM disease was associated with MSI-high status and elevated TMB. Canonical driver alterations were largely shared between groups, and Phenolyzer analysis revealed similar core oncogenic networks centered on adenomatous polyposis coli (APC), tumor protein p53 (TP53), and epidermal growth factor receptor (EGFR). In contrast, GO analysis demonstrated selective enrichment in PM tumors for molecular functions related to ATP binding, nucleotide binding, and protein kinase activity, consistent with enhanced bioenergetic demand and signaling intensity. Conclusions: These findings support refined biological stratification of mCC and the exploration of personalized, metastasis-directed strategies, potentially incorporating immunological modulation in OM disease.

1 January 2026 in Pain Research and Management
Verified
Journal Article
Open access
SCSergio Coluccia
Sergio Coluccia
ACAnna Crispo
Anna Crispo
AOAlessandro Ottaiano
Alessandro Ottaiano
MSMariachiara Santorsola
Mariachiara Santorsola
MIMassimo Antonio Innamorato
Massimo Antonio Innamorato
MCMarco Cascella
Marco Cascella
Background: Although telehealth strategies can be effectively adopted to manage cancer pain, identifying the optimal care pathway for tailoring interventions and allocating resources remains difficult. Artificial intelligence and machine learning (ML) may help clinicians develop more accurate strategies for predicting whether patients need remote consultations or in‐person evaluations. Methods: Data from two cohorts of cancer pain patients were analyzed. Variables included sociodemographic and clinical data, including age, sex, ECOG performance status, metastases, bone metastases, pain type, breakthrough cancer pain (BTCP), and rapid onset opioids (ROOs) therapy. The main outcome was the number of televisits (one versus multiple). For preprocessing, datasets from the two cohorts were harmonized by aligning variable definitions, coding schemes, and data formats. Six models were tested: logistic regression, random forest (RF), gradient boosting machine (GBM), support vector machine (SVM), k‐nearest neighbors (KNNs), and multilayer perceptron (MLP). Training and tuning used a 7‐repeated 5‐fold cross‐validation approach. Performance was evaluated on a hold‐out test set using F 1‐score, accuracy, and AUC‐ROC. A sensitivity analysis with two scenarios was performed to verify the effects of class weighting and excluding the cohort variable. Results: The final dataset included 270 patients. No statistically significant associations were identified between the available variables and the number of televisits. F 1‐scores across models ranged from 0.33 (RF) to 0.65 (MLP), accuracy from 0.45 (RF) to 0.55 (SVM), and AUC‐ROC from 0.43 (RF) to 0.65 (LR). DeLong tests showed no significant differences between algorithms ( p > 0.05). Although the MLP achieved the highest F 1‐score, it exhibited instability, with 91% of null F 1‐scores. Incorporating class weights slightly improved SVM ( F 1 = 0.58 and AUC = 0.62) and LR ( F 1 = 0.53 and AUC = 0.63) though not significantly. Conclusion: Although no model demonstrated strong predictive power, this ML‐based framework shows the potential of using structured telemedicine data to model clinical workload and optimize follow‐up strategies in cancer pain care. Trial Registration: ClinicalTrials.gov identifier: NCT04726228 and NCT07038434